(Q35954798)

11 August 2017

A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients (English)

1 reference

11 August 2017

1 reference

Aminah Jatoi

1

1 reference

11 August 2017

Carmen Radecki Breitkopf

2

1 reference

11 August 2017

Nathan R Foster

3

1 reference

11 August 2017

Matthew S Block

4

1 reference

11 August 2017

Megan Grudem

5

1 reference

11 August 2017

Andrea Wahner Hendrickson

6

1 reference

11 August 2017

Rachel E Carlson

7

1 reference

11 August 2017

Brigitte Barrette

8

1 reference

11 August 2017

Nina Karlin

9

1 reference

11 August 2017

Alan P Fields

10

1 reference

11 August 2017

6 December 2014

1 reference

11 August 2017

1 reference

11 August 2017

88

1 reference

11 August 2017

4

1 reference

11 August 2017

208-213

1 reference

Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets--where are we now?

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4536897

Atypical protein kinase Cι as a human oncogene and therapeutic target

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4536897

PKCι maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4536897

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4536897

Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4536897

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4536897

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4536897

Rising cancer antigen 125 level and the type and timing of treatment for recurrent ovarian cancer: a clinical dilemma, but what would women do?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4536897

Efficacy and safety of auranofin in patients with active early rheumatoid arthritis

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25502607

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1159/000369257

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

25502607

1 reference